These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22130903)

  • 41. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7.
    Amare Kadam PS; Varghese C; Bharde SH; Narasimhamoorthy NK; Desai S; Advani SH; Havaldar R; Kulkarni JN
    Cancer Genet Cytogenet; 2001 Mar; 125(2):139-46. PubMed ID: 11369057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer.
    Diaz LK; Gupta R; Kidwai N; Sneige N; Wiley EL
    J Histochem Cytochem; 2004 Apr; 52(4):501-7. PubMed ID: 15034001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
    Hirsch FR; Herbst RS; Olsen C; Chansky K; Crowley J; Kelly K; Franklin WA; Bunn PA; Varella-Garcia M; Gandara DR
    J Clin Oncol; 2008 Jul; 26(20):3351-7. PubMed ID: 18612151
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
    Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
    Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.
    Varella-Garcia M; Diebold J; Eberhard DA; Geenen K; Hirschmann A; Kockx M; Nagelmeier I; Rüschoff J; Schmitt M; Arbogast S; Cappuzzo F
    J Clin Pathol; 2009 Nov; 62(11):970-7. PubMed ID: 19861557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
    Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
    Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys.
    Keppens C; Schuuring E; Dequeker EMC
    Virchows Arch; 2021 May; 478(5):995-1006. PubMed ID: 33225398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.
    Tímár J; Hegedüs B; Rásó E
    Curr Cancer Drug Targets; 2010 Dec; 10(8):813-23. PubMed ID: 20718705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
    Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
    J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
    Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
    Lièvre A; Bachet JB; Le Corre D; Boige V; Landi B; Emile JF; Côté JF; Tomasic G; Penna C; Ducreux M; Rougier P; Penault-Llorca F; Laurent-Puig P
    Cancer Res; 2006 Apr; 66(8):3992-5. PubMed ID: 16618717
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
    Vidal L; Tsao MS; Pond GR; Cohen EE; Cohen RB; Chen EX; Agulnik M; Hotte S; Winquist E; Laurie S; Hayes DN; Ho J; Dancey J; Siu LL
    Head Neck; 2009 Aug; 31(8):1006-12. PubMed ID: 19309723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.
    Savic S; Tapia C; Grilli B; Rufle A; Bihl MP; de Vito Barascud A; Herzog M; Terracciano L; Baty F; Bubendorf L
    Br J Cancer; 2008 Jan; 98(1):154-60. PubMed ID: 18087280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis.
    Rákosy Z; Vízkeleti L; Ecsedi S; Vokó Z; Bégány A; Barok M; Krekk Z; Gallai M; Szentirmay Z; Adány R; Balázs M
    Int J Cancer; 2007 Oct; 121(8):1729-37. PubMed ID: 17594688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.
    Tack V; Ligtenberg MJ; Tembuyser L; Normanno N; Vander Borght S; Han van Krieken J; Dequeker EM
    Oncologist; 2015 Mar; 20(3):257-62. PubMed ID: 25657200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
    Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
    Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.